Granted Patent
B2
US 12,378,232 · App. 17/544,303 · Granted Aug 5, 2025
Cyclin dependent kinase inhibitors
Inventors:
Ping Chen (San Diego, CA); Sujin Cho-Schultz (San Diego, CA); Judith Gail Deal (San Diego, CA); Gary Michael Gallego (San Diego, CA); Mehran Jalaie (San Diego, CA); Robert Steven Kania (Del Mar, CA); Sajiv Krishnan Nair (San Diego, CA); Sacha Ninkovic (San Diego, CA); Suvi Tuula Marjukka Orr (San Diego, CA); Cynthia Louise Palmer (La Mesa, CA)
Assignee:
Pfizer Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R 1 to R 23 , A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
Claims (2)
1. A compound, which is 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol, wherein one or more hydrogen atoms are replaced by deuterium.
2. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier.
Assignments (1)
ASSIGNEE ADDRESS CORRECTION
Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →
Continuity (6)
Provisional Application
62826609
· Mar 29, 2019
Provisional Application
62750454
· Oct 25, 2018
Provisional Application
62663096
· Apr 26, 2018
References Cited (58)
US 7615562B2
· Bollbuck et al.
· 2009
[cited by applicant]
US 7855211B2
· Coates et al.
· 2010
[cited by applicant]
US 8227478B2
· Gong et al.
· 2012
[cited by applicant]
US 8618103B2
· de Vicente Fidalgo et al.
· 2013
[cited by applicant]
US 9376450B2
· Allen et al.
· 2016
[cited by applicant]
US 20040171630A1
· Kim et al.
· 2004
[cited by applicant]
US 20160264552A1
· Ciblat et al.
· 2016
[cited by applicant]
CN 105111191
· 2015
[cited by applicant]
EA 026269
· 2017
[cited by applicant]
RU 2006105338
· 2007
[cited by applicant]
WO 200119798
· 2001
[cited by applicant]
WO 200164642
· 2001
[cited by applicant]
WO 2005012256
· 2005
[cited by applicant]
WO 2006038001
· 2006
[cited by applicant]
WO 2006050076A1
· 2006
[cited by applicant]
WO 2008024390
· 2008
[cited by applicant]
WO 2009158571
· 2009
[cited by applicant]
WO 2009110254
· 2010
[cited by applicant]
WO 2011090760
· 2011
[cited by applicant]
WO 2012129562
· 2012
[cited by applicant]
WO 2013184757
· 2013
[cited by applicant]
WO 2014160017
· 2014
[cited by applicant]
WO 2015030847
· 2015
[cited by applicant]
WO 2016015604
· 2016
[cited by applicant]
WO 2016105118
· 2016
[cited by applicant]
WO 2016192630
· 2016
[cited by applicant]
WO 2016210296A1
· 2016
[cited by applicant]
WO 2017041535A1
· 2017
[cited by applicant]
WO 2017114510
· 2017
[cited by applicant]
WO 2017114512A1
· 2017
[cited by applicant]
WO 2017133701
· 2017
[cited by applicant]
WO 2018013867
· 2018
[cited by applicant]
WO 2018161033
· 2018
[cited by applicant]
WO 2019057123
· 2019
[cited by applicant]
Cooper, A. B., et al., “A unique function for cyclin D3 in early B cell development”, Nat. Immunol., (2006), 5(7):489-497.
[cited by applicant]
Cordon-Cardo, C., “Mutations of cell cycle regulators: biological and clinical implications for human neoplasia”, Am. J. Pathol., (1995), 147:545-560.
[cited by applicant]
Hall, M., Peters, G., “Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer”, Adv. Cancer Res., (1996), 68:67-108.
[cited by applicant]
Johnson, D. G., Walker, C.L., “Cyclins and Cell Cycle Checkpoints”, Annu. Rev. Pharmacol. Toxicol., (1999), 39:295-312.
[cited by applicant]
Karp, J. E., Broder, S., “Molecular foundations of cancer: new targets for intervention”, Nat. Med., (1995), 1:309-320.
[cited by applicant]
Malumbres, M., et al., “Mammalian Cells Cycle without the D-type Cyclin-Dependent Kinases Cdk4 and Cdk6”, Cell, (2004), 118(4): 493-504.
[cited by applicant]
Morgan, D. O., “Cyclin-dependent kinases: engines, clocks, and microprocessors”, Annu. Rev. Cell. Dev. Biol., (1997), 13:261-291.
[cited by applicant]
Ortega, S., et al., “Cyclin D dependent kinases, INK4 inhibitors and cancer”, Biochim. Biophys. Acta, (2002), 1602:73-87.
[cited by applicant]
Sánchez-Martínez, C., et al., “Cyclin dependent kinase (CDK) inhibitors as anticancer drugs”, Bioorg. Med. Chem. Lett. (2015), 25:3420-3435.
[cited by applicant]
Sicinska, E., et al., “Essential Role for Cyclin D3 in Granulocyte Colony-Stimulating Factor-Driven Expansion of Neutrophil Granulocytes”, Mol. Cell Biol., (2006), 26(21):8052-8060.
[cited by applicant]
Smalley, K. S. M., et al., “Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression”, Cancer Res., (2008), 68:5743-52.
[cited by applicant]
Zuo, L., et al., “Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma”, Nature Genet., (1996), 12:97-99.
[cited by applicant]
International Search Report for PCT/IB2019/053314, mailed on Jul. 29, 2019.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT/IB2019/053314, prepared on Jul. 29, 2019.
[cited by applicant]
Federal Institute of Industrial Property (FIPS) Search Report for Russian Application No. 2020134811, based on PCT/IB2019/053314, dated Mar. 29, 2021 and English translation.
[cited by applicant]
National Centre of the Intellectual Property of Georgia, Search Report for Georgian Application No. AP 2019 15475, based on PCT/IB2019/053314, dated May 28, 2021 and English translation.
[cited by applicant]
Packard et al., Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors; Bioorganic & Medicinal Chemistry; (2012), 22(1), 747-752.
[cited by applicant]